Prime Medicine (NYSE:PRME) vs. ZIVO Bioscience (NASDAQ:ZIVO) Financial Contrast

ZIVO Bioscience (NASDAQ:ZIVO) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for ZIVO Bioscience and Prime Medicine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0	0	0	0	0.00
Prime Medicine	0	3	4	0	2.57

Prime Medicine has a consensus target price of $7.21, indicating a potential upside of 64.57%. Given Prime Medicine’s stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than ZIVO Bioscience.

Volatility and Risk

ZIVO Bioscience has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500.

Profitability

This table compares ZIVO Bioscience and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Prime Medicine	N/A	-107.87%	-74.97%

Insider and Institutional Ownership

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares ZIVO Bioscience and Prime Medicine”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15,850.00	2,397.48	-$7.78 million	($2.18)	-4.36
Prime Medicine	$5.98 million	132.28	-$198.13 million	($1.44)	-3.04

ZIVO Bioscience has higher earnings, but lower revenue than Prime Medicine. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Summary

Prime Medicine beats ZIVO Bioscience on 9 of the 13 factors compared between the two stocks.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.